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ABSTRACT 
Dosage compensation (the equalisation of X-linked gene products) occurs in 
Drosophila melanogaster by a two fold transcriptional up-regulation of X-lir.ked gene 
expression in males. This involves the binding of five proteins, MSL-1 , MSL-2, MSL-
3, MLE, MOF, and potentially an RNA (roXJ or roX2), to hundreds of sites along the 
male X chromosome. The cis-acting X-linked DNA sequences required for dosage 
compensation ( called dosage compensation regulatory elements or DCREs) remain 
elusive, despite numerous attempts of identify them. An insulated reporter gene assay 
system has been developed to minimise problems previously encountered with 
identification of these elements. The reporter system consists of the constitutive 
armadillo promoter fused to the lacZ reporter gene ( called arm-lacZ). This reporter 
construct is flanked by SCS/SCS' insulator elements to block potential repressive 
effects of an autosornal chromatin environment. 
The role of the roX genes during dosage compensation was investigated. Initially both 
the roXJ and roX2 RNAs were expressed from within the arm-lacZ insulated system. 
Expression of either RNA lead to a significant increase in lacZ expression in males, 
although consistently less than two-fold. These results suggested that either the MSL 
complex was binding to the roX genes or the expression of the roX RNAs in cis lead to 
male-specific hypertranscription of lacZ. To test these possibilities roXI and roX2 
cDNAs were inserted into the arm-lacZ reporter. Insertion of either cDNA lead to a 
significant increase in lacZ expression in males, suggesting that the transcribed regions 
of the roX genes contain binding site(s) for the MSL complex. Interestingly the level of 
lacZ hypertranscription in males was significantly higher in homozygous roXI cDNA 
lines than homozygous roXJ gene lines. This may indicate that too high a local 
concentration of roXJ RNA has a dampening effect on the level of hypertranscription 
meditated by the MSL complex. In a set of experiments designed to identify the MSL 
binding site(s) in roXJ, two regions of the cDNA sequence were amplified and inserted 
into the arm-lacZ system. One of these fragments, containing a proposed DNAsel 
hypersensitivity site and possible GAGA binding sites, increased lacZ expression in 
males, but to levels lower than the entire cDNA. This suggests there may be more than 
one MSL biding site in roXI. 
111 
A second method of dosage compensation 1s thought to occur in Drosophila, 
independentiy of the MSL proteins. The arm-lacZ insulated reporter system was used 
to investigate the hypothesis that some genes may be dosage compensated due to 
repression by Sex-lethal (Sxl) in females. Several genes have been found to contain 
three or more Sxl binding sites in their 3' UTRs, with some also carrying Sxl binding 
sites in the 5' UTR. Fragments from the Sxl, Cut and Small Forked genes, containing 
numerous Sxl binding sites from the 3' UTR, were inserted into the 3' UTR region of 
arm-lacZ. Males carrying autosomal insertions of the construct had on average 1.07 -
1.50 times the level of 13-galactosidase in females. This suggests that some genes could 
be partially compensated through Sxl repression in females. 
In addition to inserting 3' UTR fragments into arm-lacZ, a synthetic oligonucleotide 
containing a long Sxl binding site was inserted into the 5' region of an arm-lacZ 
construct already carrying the Runt 3' UTR fragment. Males carrying autosomal 
insertions of the construct had levels of 13-galactosidase activity similar to those lines 
carrying autosomal insertions of the 3' UTR fragments alone. This suggests that other 
factors such as RNA binding proteins or RNA secondary structure may be required in 
order to obtain efficient translation repression by Sxl. 
Finally three X-linked DNA fragments, from the 1 C region, were inserted individually 
between the SCS' element and the armadillo promoter. If the X-linked fragment 
contained a DCRE then males carrying autosomal insertions of the construct would 
produce twice the 13-galactosidase activity of females. However, males and females 
expressed the same levels of lacZ. 
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p beta 
~ delta 
"- lambda 
oc degrees Celsius 
ATP adenine triphosphate 
bp base pairs 
BSA bovine serum albumin 
cDNA complementary DNA 
DIG digoxigenin 
DNA deoxyribose nucleic acid 
DNAse deoxyribonuclease 
dNTPs dinucleotide triphosphates 
F female 
g gram 
L litre 
kb kilo base pairs 
µ m1cro 
m milli 
M male or molar 
mRNA messenger RNA 
nt nucleotide pairs 
OD optical density 
PCR polymerase chain reaction 
RNA ribonucleic acid 
RNase ribonuclease 
rpm revolutions per minute 
u unit 
UTR untranslated region 
UV ultra violet 
v/v volume per volume 
w/v weight per volume 
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1.0 INTRODUCTION 
H DOSAGE COMPENSATION - AN OVERVIEW 
Dosage compensation is the mechanism by which the expression of X-linked genes is 
equalised between males with one X chromosome and females with two. Different 
organisms have evolved unique mechanisms to achieve dosage compensation. In 
mammals one female X chromosome is randomly inactivated to equal the expression of 
the single male X chromosome (Lyon, 1961). In Caenorhabditis elegans the expression 
of both female X chromosomes is down regulated to equal the expression of the single 
male X chromosome (Hsu and Meyer, 1993). Mammals and C. elegans are both 
examples of organisms where the male is the heterogametic sex. In organisms where 
the female is heterogametic (ZW), eg. birds and butterflies, dosage compensation has 
been shown not to occur (Baverstock et al. , 1982; Johnson and Turner, 1979). 
1.2 DOSAGE COMPENSATION IN DROSOPHILA 
1.2.1 Dosage Compensation Involves Transcriptional Up Regulation 
In Drosophila dosage compensation is achieved by the hypertransactivation 
(transcriptional up-regulation) of genes on the single male X chromosome to equal the 
level of expression from two female X chromosomes. Early support for this statement 
came from Offermann's, (1936) observation in squashes of polytene chromosomes, 
from larval salivary glands, that the male X chromosome is wider and more diffuse in 
appearance than both female X chromosomes. This 'puffier' appearance indicates an 
increase in gene expression. Following this observation Mukherjee and Beermann, 
( 1965) demonstrated that incorporation of tritiated (3H) uridine into nascent salivary 
gland transcripts was significantly higher in the single unpaired male X chromosome 
than one female X chromosome. Results from these experiments pointed to an 
enhancing effect occurring on the male X chromosome rather than a repressing effect on 
the female. 
2 
1.2.2 Histone Acetylation, Transcriptional Activity and Dosage Compensation 
The core particle of the nucleosome consists of four histones H2A, H2B, H3 and H4. 
Acetylation e)f the histones occurs at specific lysine residues in the N-terminal domain 
and is a ubiquitous post-translational modification found in all animal and plant species 
(Turner, 1991). 
Histone acetylation has been stated as being potentially a maJor influence on 
transcription and DNA packaging through the cell cycle (Turner, 1991). Histones in 
actively transcribing genes are rapidly acetylated and deacetylated, which proposes a 
link between transcriptional activation and histone acetylation (reviewed by Turner, 
1991). Neutralisation of positive charges by acetylation ofhistone H4 is thought to play 
a primary role in altering interactions between the DNA and histones, which may 
mediate enhanced binding of transcription factors to their DNA target sequences 
(Vettese-Dadey et al., 1996). 
Acetylation of E-amino groups of lysine residues, present in the N-terminal domain of 
the core histones, is most strongly linked with transcriptional activity (Turner, 1991). 
Vettese-Dadey et al. , (1996) demonstrated that the highly acetylated histone H4 in 
nucleosome cores has the highest affinity for transcription factors USF and GAL-4H. 
Studies of the Saccharomyces cerevisiae mating type (MAT) locus (Johnson et al., 
1990) indicates that the repression of the silent mating loci requires histone acetylation. 
When lysine 16 is mutated to an arginine, which retains the positive charge, the 
regulation of the MAT locus is unaffected. But, when lysine 16 is mutated to a 
glutarnine (a neutral amino acid mimicking acetylation) derepression of the locus occurs 
(Johnson et al., 1990). A specific isoform of histone H4 acetylated at lysine 16 
(H4Ac 16) is also predominantly associated with the male X chromosome in Drosophila 
(Turner et al., 1992). The acetylation of histone H4 on lysine 16 (H4Acl 6) may play a 
role in loosening the chromatin structure and increasing the accessibility of transcription 
factors associated with the male X chromosome in Drosophila (Bone et al., 1994). 
3 
1.3 THE TRANS-ACTING MALE SPECIFIC LETHALS 
A simple model for dosage compensation in Drosophila would predict that increases in 
X-linked gene transcription result from the action of trans-acting factors upon target 
cis-acting sequences localised to the X chromosome (Palmer et al. , 1993). It has been 
rationalised that mutations inactivating regulatory genes responsible for dosage 
compensation could result in sex specific lethality (Lucchesi and Manning, 1987). A 
mutation that prevents normal compensation could cause the death of an individual with 
a single X chromosome due to a deficiency of X-linked gene products. Belote and 
Lucchesi, (1980a) carried out a large screen for ethyl methanesulfonate (EMS) induced 
sex-specific lethals on the 2nd and 3rd chromosomes. Three male-specific lethal 
mutations male-specific lethal-I (msl-1) , male-specific lethal-2 (msl-2) and maleless 
(mle) were discovered. Temperature sensitive mutants of mle had previously been 
isolated from natural populations of D. melanogaster (Fukunaga et al. , 1975; 
Golubovsky and Ivanov, 1972). These three genes plus the subsequently discovered 
male-specific lethal-3 (msl-3) (Lucchesi et al., 1982) and males-absent on the first (mof) 
(Hilfiker et al. , 1997) have been collectively named the male-specific lethals or msls. 
Males mutant in any of these genes exhibit prolonged posthatching development and 
eventually die during the late larval or early pupal stages (Belote, 1983). These 
mutations have been shown to have no discernible effect on the viability and 
development of females (Belote and Lucchesi, 1980a). 
Males homozygous for msl-1, msl-2 or mle show a significant reduction in X-linked 
enzyme activities, while the levels of autosomal enzymes are not affected (Belote and 
Lucchesi, 1980b ). 
The MSL proteins bind to hundreds of sites along the entire length of the male X 
chromosome (Kuroda et al., 1991; Palmer et al., 1993 ). Immuno localisation 
experiments show that the MSLs bind to the same sites along the X chromosome (Bone 
et al., 1994), and the native X chromosome binding of any MSL protein requires the 
wildtype function of the other four MSLs (Bashaw and Baker, 1995; Gorman et al. , 
1993; Gu et al. , 1998; Hilfiker et al., 1994; Kelley et al., 1995; Palmer et al., 1994,). 
This dependent binding suggests that the MSL proteins form a heteromultimeric 
complex. 
4 
1.3.1 Maleless 
As discussed above the ms/ genes have all recently been cloned. The mle gene (Kuroda 
et al., 1991} encodes a polypeptide containing several short motifs characteristic of a 
superfamily of DNA and RNA helicases. MLE shows the highest sequence homology 
to a subfamily of RNA helicases containing DEAH box motifs (Schwer and Guthrie, 
1991; Nakajima et al. , 1997). MLE shares 50% identity with human RNA helicase A 
(RHA) which mediates the interaction of CBP (CREB Binding Protein) with RNA 
polymerase II (Nakajima et al., 1997). It has been proposed that the recruitment of CBP 
complexes may promote local unwinding of promoter DNA via RHA and allow access 
of transcriptional apparatus (Nakajima et al. , 1997). A study by Lee et al. , (1997) 
showed that MLE possesses NTPase and both RNA and DNA helicase activities and 
that these activities are essential functions of MLE for dosage compensation. 
Preliminary studies by Nakajima and Montminy (unpublished data cited by Nakajima et 
al., 1997) have observed MLE associating with a 250 kDa CBP with histone acetylase 
activity. The unpublished data along with evidence that MLE appears to co-localise 
with acetylated histone H4 (Bone et al. , 1994), and has NTPase/helicase activity (Lee et 
al. , 1997) suggests that MLE may be involved in initiation of transcription, perhaps via 
chromatin remodelling ofX-linked genes. 
1.3.2 Male-Specific Lethal-I 
The cloning and characterisation of the msl-1 gene (Palmer et al., 1993) showed that the 
MSL-1 protein is not closely related to any proteins in the current databases. It does 
however contain acidic regions in the N-terminus consisting of two extended aspartate 
and glutamate clusters, characteristic of proteins involved in chromatin modelling and 
transcription (Palmer et al., 1993). The acidic regions of these proteins may provide a 
region of interaction with histones to mediate nucleosome assembly or release and 
thereby promote changes in chromatin structure and transcription ·(Palmer et al., 1994; 
Turner et al. , 1992). MSL-1 protein is present in mle and ms/-3 mutant larvae, but is 
undetectable in ms/-2 mutant male larvae (Palmer et al., 1994). This finding plus other 
genetic tests carried out by Palmer et al., (1994) suggests that ms/-2 expression 
positively regulates the translation or stability of MSL-1 in males. MSL-1 also contains 
regions rich in proline, serine, threonine and glutamic acid which are residues (PEST 
sequences) associated with rapidly degraded proteins (Palmer et al., 1993). 
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1.3.3 Male-Specific Lethal-2 
MSL-1 and MSL-2 have been shown to co-immunoprecipitate from male nuclear 
extracts (Kelley et al. , 1995). MSL-2 (Zhou et al., 1995), contains a RING finger, 
which is a C3HC4 zinc finger (Lovering et al., 1993). Using a two-hybrid system Copps 
et al. , (1998) found that the RING finger domain of MSL-2 binds MSL-1. When 
residues clustered around the first zinc-binding site of the RING finger domain in MSL-
2 were mutated interaction with MSL-1 was lost. In addition to the RING finger motif 
the MSL-2 protein also contains a positively and a negatively charged amino acid 
residue cluster and a coiled coil domain that may be involved in protein-protein 
interactions (Zhou et al., 1995). Zhou et al., (1995) hypothesise that MSL-2 may be a 
transcription regulator, with the positively charged amino acid cluster contributing to a 
DNA binding domain and the negatively charged cluster being part of a transcription 
trans-activator domain. Copps et al., (1998) propose that the RING finger domain 
interaction with MSL-1, through the first zinc-binding site, may be an important 
prerequisite for subsequent protein-protein interactions and that the second zinc-binding 
site may have a second, but as yet unidentified activity. 
MSL-1 and MSL-2 appear to form a core complex within the MSL complex. When 
either is removed through mutation the remaining MSL proteins fail to bind any site 
along the X chromosome (Gorman et al., 1993; Gorman et al., 1995; Palmer et al., 
1994; Lyman et al. , 1997). Conversely if MSL-3, MLE or MOF are removed MSL-1 
and MSL-2 remain bound to 30 - 40 'high affinity' binding sites along the X 
chromosome (Palmer et al. , 1994; Gorman et al., 1995; Gu et al. , 1998; Lyman et al. , 
1997) 
1.3.4 Male-Specific Lethal-3 
Cloning and characterisation of the msl-3 gene found that it encodes a novel protein 
(Gorman et al., 1995). MSL-3 contains two chromatin organisation modifier (chromo) 
domains that are 30 - 50 amino acid domains conserved in several eukaryotic 
chromatin-binding proteins such as Drosophila hetereochromatin protein 1 (HPl) and 
Polycomb (PC) (Koonin et al., 1995). Chromodomains have been implicated in the 
delivery of both positive and negative transcription regulators to chromatin targets. 
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1.3.5 Males-Absent on the First 
Experimental results have identified an additional gene males-absent on the first (moj) , 
which encodes a putative histone acetyl transferase thought to be crucial for dosage 
compensation. This fifth male lethal gene was isolated by screening the X chromosome 
of Drosophila melanogaster for EMS-induced mutations, to identify genes carrying 
mutations that cause male specific lethality. Males mutant for mof die at the third instar 
larval stage of development, MSL-1 , MSL-2 and MLE association with the X 
chromosome is reduced and the X-specific isoform of H4Ac16 is absent (Hilfiker et al., 
1997). 
The mof mRNA encodes an 827 amino acid protein that contains a 250 amino acid 
domain common to many acetyl transferases and is shown to be required for binding of 
acetyl coenzyme A. This domain is found in proteins known to acetylate histones, such 
as histone acetyl transferase 1 of yeast (Kleff et al. , 1995) and histone acetyl transferase 
A of Tetrahymena (Brownell et al., 1996). The mutation of mof results from a 
substitution of Gly691 (the most conserved residue in the 250 amino acid motif) for 
glutamic acid. This mutation leads to the absence of H4Ac16 on the male X 
chromosome and a male lethal phenotype. Lu et al. , (1996) showed that the mutation of 
the corresponding glycine to an aspartate, in the human spermidine/spermine acetyl 
transferase, abolishes enzyme activity. Recently it has also been demonstrated that 
MOF co-localises with the MSL complex on the male X chromosome using loss-of-
function mutations (Gu et al. , 1998). 
Immunolocalisation experiments have shown that all of the MSL proteins bind to 
hundreds of specific sites along the male X chromosome. Each of the MSLs is 
produced in both sexes except for MSL-2, which is absent in females (Zhou et al. , 
1995). Henikoff and Meneely, (1993) suggest that MLE could catalyse the movement 
of the MSL complex along the nascent RNA. In msl-1, msl-2 or msl-3 mutant 
backgrounds MLE does not bind the X chromosome, but is still present, indicating that 
MSL-1, MSL-2 and MSL-3 are required for binding, but not for regulation of X 
chromosome expression (Gorman et al., 1993). MOF, the fifth MSL protein, encodes a 
putative histone acetylase. Mutational studies provide strong evidence that MOF has 
histone acetyl transferase activity and is responsible for the histone acetylation involved 
in male specific hypertranscription of X-linked genes (Hilfiker et al., 1997). 
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1.3.6 Histone Acetylation and MSL Localisation 
The pattern of H4Acl 6 distribution on the X chromosome is very similar to that of the 
MSLs suggesting a link between the signals required for localising these proteins to the 
male X chromosome (Bone et al. , 1994). Bone et al., (1994) also observed that 
presence of this H4 isoform on the X chromosome requires the wildtype function of the 
ms! genes. This suggests that the mechanism of dosage compensation involves histone 
acetylation through association with the MSL proteins. 
1.4 NON-CODING RNA INVOLVEMENT IN DOSAGE COMPENSATION 
Two new genes roXI and roX2 (RNA Qn the X chromosome) have been isolated using 
an enhancer detector screen for ~-galactosidase activity in the mushroom bodies of the 
Drosophila brain (Amrein and Axel, 1997; Meller et al., 1997). Both genes are X-
linked and each encodes an RNA without a significant open reading frame (ORF). 
Their expression is confined to the nucleus of male flies, which suggests that they may 
encode non-coding RNAs (Amrein and Axel, 1997; Meller et al. , 1997). Expression of 
roXI and roX2 is dependent on the MSL complex ( dosage compensation machinery) as 
neither of the genes are expressed in flies mutant for any of the msls. Additionally, 
expression of a msl-2 transgene in females induces the expression of both roXI and 
roX2 RNA (Amrein and Axel, 1997; Meller et al. , 1997). In situ hybridisation of roXI 
probes to late third-instar male larvae salivary gland X chromosomes displays a 
subcellular localisation of roXI RNA very similar to the localisation of the MSL 
complex binding the X chromosome (Amrein and Axel, 1997; Meller et al., 1997). 
Disruption of roXI produces no obvious phenotype, lethality, or developmental delay, 
which rules out roXI as an essential component of the dosage compensation complex. 
However the disrupted roXJ mutant (the roxrx6 mutation removes the 5' half of the 
roXI gene and produces no stable RNA (Kelley et al. , 1999)) was used to show that 
roXJ RNA could spread in trans. Kelley et al. , (1999) inserted a DNA fragment, 
containing the roXI gene, into either the second or third chromosome by P element 
mediated transformation. Males homozygous or hemizygous for the null roxrx6 
mutation, but carrying one copy of the roXI transgene, were used for RNA in situ 
hybridisation to polytene chromosomes. These in situ experiments showed the 
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autosomally encoded RNA coating the entire X chromosome. This indicates that the 
roXJ RNA still bound to the X despite being produced on another chromosome. 
Kuroda et al., (1991) proposed an RNA component of the dosage compensation system 
based on the observations that MLE contains RNA binding domains and is released 
from the X chromosome by RNase digestion (Richter et al. , 1996). However male flies 
mutant for roXJ exhibit normal MLE binding and are fully dosage compensated (Meller 
et al., 1997). 
Franke and Baker, (1999) genetically produced a mutant with simultaneous loss of both 
roXJ and roX2, which abolished binding of the MSL complex to the male X 
chromosome. They suggest this is a strong indication that the roX RNAs are integral 
components of a dosage compensation nucleoprotein complex and is consistent with the 
earlier proposal of Meller et al., (1997) that there is a family of non-homologous and 
redundant genes including roXJ and roX2 that can compensate for the loss of one of its 
members. They also propose that roXJ and its family members associate along the 
entire X chromosome to help change chromatin conformation and achieve 
hypertranscription, perhaps by associating with the MSLs, histone acetyl transferase or 
other chromatin constituents. 
Comparisons have been made between the roX RNA and Xist RNA that coats the 
inactive mammalian X chromosome. Xist encodes a non-coding RNA expressed from 
the X-inactivation centre of the inactive X chromosome in mammals and is thought to 
'spread' (in cis) along one of the female X chromosomes, remodelling chromatin to form 
a transcriptionally inactive Barr body (Lee et al. , 1996). There are some similarities 
between roXJ and Xist; they are both nuclear and localised to a structurally modified X 
chromosome undergoing dosage compensation (Meller et al., 1997). 
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1.5 REGULATION OF DOSAGE COMPENSATION 
1.5.1 Sex-Lethal 
The process of dosage compensation is one of several controlled by the 'master 
regulatory gene' Sex-lethal (Sxl). Initially dosage compensation is controlled by the 
expression patterns of Sxl, which in turn is controlled by the ratio of X chromosomes 
(X) to autosomes (A). An X:A ratio of 1.0 (2X:2A) results in female development and 
a X:A ratio of 0.5 (1X:2A) results in male development. In Drosophila the X:A ratio 
acts to switch the Sxl gene into either the female mode which represents ON 
(functional) or the male mode which represents OFF (non-functional) (Cline, 1978). 
The X:A ratio itself is assessed by 'counting' genes, referred to as numerators and 
denominators (reviewed by Parkhurst and Meneely, 1994). These proteins are members 
of the helix-loop-helix (HLH) family of transcription factors (Parkhurst et al. , 1990). 
The numerators are a group of X chromosomal genes that behave as feminising 
elements because they increase the probability of activating Sxl expression. Lowering 
the number of numerators results in female lethality due to the lack of activated Sxl, 
whereas raising the number results in male lethality because Sxl is activated. 
Denominators are autosomally encoded genes acting as antagonists to the numerators 
by competing with numerators to form heterodimers. The heterodimers formed activate 
Sxl at the level of transcription (Keyes et al., 1992). 
The initial activation of Sxl results in production of Sxl mRNA transcripts from the early 
'establishment' promoter PE in females. These early Sxl mRNA protein products specify 
the production of active female-specific transcripts from the late 'maintenance' promoter 
PL (Bell et al., 1991) and thereby establish an autoregulatory feedback loop. Transcripts 
of Sxl are also produced in males from PL' but these are truncated and inactive and 
maintained by default (Bell et al., 1991; Keyes et al., 1992). 
In males a functional Sxl protein is missing, therefore male differentiation and dosage 
compensation occurs. In females, active Sxl protein acts upon the m.RNA of 
transformer (tra), the next gene in the pathway. Sxl binding to tra RNA blocks a splice 
acceptor site, resulting in another female-specific splicing pattern occurring. The 
functional Tra protein is only produced in females and is involved in somatic sex 
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determination. In vitro studies by Samuels et al. , (1994) showed that Sxl protein binds 
to poly uridine (polyU) tracts in mRNA that consist of eight or more Us or AU7• 
1.5.2 Sxl Regulation of Dosage Compensation 
Sxl loss-of-function mutations cause female lethality and gain-of-function mutations 
cause male lethality (Cline, 1978). Zhou et al., (1995) demonstrated that the primary 
target of Sxl during dosage compensation is msl-2. The msl-2 transcript is present in 
both males and females, with the same ORF, but the MSL-2 protein is present only in 
males (Bashaw and Baker, 1995; Kelley et al. , 1995; Zhou et al. , 1995). A small intron 
in the 5' UTR (untranslated region) of the msl-2 transcript is spliced out in males and 
retained in females (Bashaw and Baker, 1995; Kelley et al., 1995; Zhou et al., 1995). 
Within this intron are poly(U) runs that resemble the Sxl binding sites found in Sxl and 
tra and are therefore spliced out in males. Four more Sxl binding sites are present in the 
3' UTR that is retained in both sexes. Mutations of Sxl binding sites in either the 5' or 
the 3' regions result in ectopic expression of MSL-2 protein in females. This indicates 
that the sites in both the 3' and 5' UTRs are required for appropriate regulation of msl-2 
translation (Bashaw and Baker, 1997; Kelley et al. , 1997). Bashaw and Baker, (1997) 
suggest the possibility that Sxl binding at both ends of the msl-2 transcript changes the 
structure of the RNA by circularisation and therefore prevents access of translational 
machinery. 
1.5.3 A Second MSL Independent Method of Dosage Compensation 
A second method of dosage compensation has been suggested in Drosophila that is 
independent of the msls. The first evidence for this second method was the observation 
by Cline, (1978) that females homozygous for a loss-of-function mutation for Sxl were 
not rescued if also homozygous for mutations in msl-2, msl-1 or mle. msl-3 is yet 
untested, but assumed to have the same phenotype due to the co-dependence of the 
msls. These findings suggest that Sxl and the msls may act on different loci to direct 
dosage compensation. 
Dosage compensation of the X-linked Runt gene has been shown to be dependent on 
Sxl, but independent of the msls (Gergen, 1987; Bernstein and Cline, 1994). Wildtype 
Runt is required for the normal segmentation of Drosophila embryos (Gergen and 
Wieshaus, 1986) and is active at the blastoderm stage. Gergen, ( 1987) studied the 
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dosage compensation of Runt at the blastodenn stage of development and found that 
Runt expression was not affected by mutations in msl-1, ms/-2 and mle. Examination of 
the Runt gene- revealed three Sxl binding sites in the 3' UTR (Kelley et al., 1995). Sxl 
expression from the early Sx/ promoter (SxlE) occurs at the same stage of development 
as Runt expression, which supports the idea that early dosage compensation begins at 
mid-stage four and that Runt expression is Sxl dependent and ms/ independent 
(Bernstein and Cline, 1994; Gergen, 1987). The regulation of Runt by Sxl is probably 
due to repression of expression in females as indicated by only female-specific lethal 
alleles of Sxl affecting dosage compensation at the blastoderm stage (Gergen, 1987). 
Two models have been suggested for the relationship between MSL dependent and Sxl 
mediated dosage compensation. The first involves Sxl controlling 'early' dosage 
compensation during embryogenesis, while the MSLs mediate 'late' dosage 
compensation during the larval and pupal stages. Evidence for this model is that ms/ 
mutant males complete embryogenesis, but die as late larvae or pupae (Belote and 
Lucchesi, 1980a; Fukunaga et al., 1975) and Runt is expressed before MSLs become 
functional (Gergen, 1987). Sxl and Runt expression is detected at mid-stage four of 
embryogenesis, but MSL binding to the X chromosome does not occur until the end of 
stage five (blastoderm stage). The Sxl 'early' dosage compensation process may have 
evolved to satisfy a need for dosage compensation before the MSLs become functional 
and therefore the two systems are operating sequentially (Franke et al., 1996). 
The second model is that Sxl and MSL mediated dosage compensation pathways act in 
parallel (Rastelli et al. , 1995) during development on separate sets of genes (Kelley et 
al., 1995). Recent data suggests that Sxl may reduce the stability or translation of a 
subset of X-linked transcripts in females (Kelley et al., 1995). Kelley et al., (1995) 
suggest that this second dosage compensation system may upregulate X-linked genes in 
males, while a subset of X-linked genes are down regulated in females. A computer 
search scanning all available 3' UTRs of Drosophila genes produced 21 genes 
containing three or more 3' poly(U) sites. 20 of these genes are on the X chromosome. 
The only autosomal gene found was ms/-1 (msl-2 is also autosomal) (Kelley et al., 
1995). Kelley et al., ( 1995) proposed that Sxl directly regulates dosage compensation of 
many genes through their 3' UTRs. Bernstein and Cline, (1994) suggest that Sxl 
mediated dosage compensation is not limited to embryonic development through studies 
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of partial loss-of-function Sxl mutants, while Rastelli et al., (1995) suggest that ms/-
dependent dosage compensation is not limited to larval development. 
1.6 C/S-ACTING ELEMENTS CONTROLLING DOSAGE COMPENSATION 
Relatively little is known about the cis-acting sequence characteristics of the X 
chromosome which identify it as a target for dosage compensation regulators (ie. MSLs 
and Sxl). These dosage compensation regulatory elements (DCREs) are thought to be 
distributed throughout the X chromosome. Evidence suggests that DCREs exert their 
efforts locally on individual genes or small groups of genes. When fragments from the 
X chromosome are transposed to an autosome the X-linked genes within the fragment 
remain dosage compensated (Ghosh et al., 1989; Hazelrigg et al., 1984; Krumm et al. , 
1985; Levis et al., 1985; McNabb and Beckendorf, 1986; Pirrotta et al., 1985; Spradling 
and Rubin, 1983 ). Also when cloned X-linked genes are trans located to autosomal sites 
they remain at least partially dosage compensated (reviewed by Baker et al., 1994; 
Lucchesi and Manning, 1987). 
Conversely when autosomal fragments are translocated to X chromosome sites the 
genes within the fragment remain non-compensated. But, when cloned autosomal 
genes are translocated to the X chromosome they are compensated in males (Baker et 
al. , 1994). These observations suggest that dosage compensation in Drosophila is 
controlled by cis-acting sequences both distant and close to the genes. Supporting this 
suggestion is the observation that not all genes on the X chromosome are dosage 
compensated. These non-compensated genes can be in close proximity to genes that 
are. 
Support for the hypothesis that cis-acting elements confer transcriptional upregulation 
only onto nearby sequences is the finding that LSP-la is an X-linked gene but is not 
compensated. LSP-1 a codes the alpha subunit of larval serum protein- I. LSP-1 a has a 
transcription unit named Ll 2 immediately adjacent to it that is compensated (Ghosh et 
al., 1989). Females exhibit twice the amount of gene product found in males (Brock 
and Roberts, 1982; Roberts and Evans-Roberts, 1972). This phenomenon could be 
explained by assuming that the LSP-1 a gene has only relatively recently been 
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translocated to the X chromosome. Ghosh et al. , (1989) determined that LSP-1 a is 
inherently capable of dosage compensation by relocating the LSP-1 a gene to ectopic X 
chromosome sites. The results of this experiment showed steady state levels in males 
(one dose) are equivalent to females (two doses) . 
1.6.1 DCREs Are Still Unidentified 
For the last ten years the search for cis-acting sequences involved in dosage 
compensation has been fruitless. Two X-linked genes (white and Sgs-4) have been 
extensively studied using genetic and molecular techniques in an attempt to localise the 
DCREs. The studies predominantly involved inserting X-linked transgenes, which 
contained progressive deletions, into autosomes to isolate a possible consensus 
sequence for dosage compensation. 
Levis et al., (1985) analysed the cis-acting sequences involved in regulating the white 
gene. Varying lengths of both 3' and 5' flanking sequences were deleted from the white 
gene. Flanking sequences 420 bp upstream and 160 bp downstream of the gene were 
found to be sufficient for dosage compensation to occur. Pirrotta et al., (1985) further 
delimited the required sequence to 200 bp upstream of the gene. 
As sequences in the white gene are gradually removed from the 5' end a progressive 
decline in dosage compensation is observed (Qian and Pirrotta, 1995). Qian and 
Pirrotta, (1995) concluded that cis-acting DCREs consist of multiple elements present 
near and within the promoter and some within the coding region of the gene. Despite 
these observations no DCRE consensus sequence has been identified. 
Transformation experiments involving the Sgs-4 gene demonstrated that 840 bp 
upstream and 130 bp downstream of the gene are sufficient for proper activity and 
regulation when relocated to autosomal sites (McNabb and Beckendorf, 1986). 
Sequence comparisons between compensated and non-compensated alleles failed to 
show any base substitutions specific to the non-compensated alleles (Hofmann and 
Korge, 1987). 
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1.6.2 Mono and Dinucleotide Repeats Correlate with Dosage Compensation 
Evidence has been presented that suggests the X chromosome has unique structural 
features that · may be related to dosage compensation. Two dinucleotide repeats 
(CA/GT)" and (CT/GA)n and one mononucleotide repeat (C/G)n have been reported to 
be found at twice the level on the X chromosome as on autosomes (Huijser et al. , 1987; 
Lowenhaupt et al. , 1989; Pardue et al., 1987). Chromosomal arms from autosomes 
translocated to the X chromosome acquire the ability to dosage compensate in several 
Drosophila species. The newly translocated arm also gains a higher density of 
(CA/GT\ similar to the other X chromosomes. The pattern of (CA/GT)" sequences 
shows several correlations with general chromosomal functions such as dosage 
compensation (Pardue et al. , 1987). Pardue et al., ( 1987) suggests that the acquisition 
of dosage compensation ability and higher density of (CA/GT)" repeats reflects a 
relationship between the two processes. 
These repeats are all able to adopt a non B form of DNA when subjected to negative 
supercoiling in vitro and may be involved in the adoption or maintenance of a 
decondensed X chromatin structure required for dosage compensation (Lowenhaupt et 
al., 1989). Other than their enrichment on the X chromosome there is no evidence that 
these repeats are involved in dosage compensation as the repeats are also found on 
autosomes at significant levels. 
1.6.3 Why Have DCREs Not Been Identified? 
A major limitation of previous attempts to identify DCREs is that X-linked genes on 
autosomes are only partially compensated. 
All studies (excluding white studies) used Northern Blots or RNase Protection Assays to 
quantitate gene expression levels in males and females. These methods experience 
technical difficulties when quantitating two fold differences in expression. Studies of 
the white gene used spectrophotometric eye pigment assays that must take into account 
the non-linearity of the pigmentation response to gene dose (Qian and Pirrotta, 1995). 
Early indications of this non-linearity were demonstrated when transgenes at autosomal 
sites exhibited full dosage compensation - males with one dose produce twice as much 
pigment as one dose females. However females with two copies of the white transgene 
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have a two to three fold higher level of pigmentation than males with one (Hazelrigg et 
al. , 1984; Levis et al., 1985; Pirrotta et al. , 1985). 
Hypotheses have been suggested to account for partial dosage compensation when X-
linked transgenes are translocated to autosomes. Qian and Pirrotta, (1995) suggest that 
the requirement for a certain amount of DCREs associated with the gene is not being 
met and/or that the autosomal chromatin environment (more condensed than X 
chromosomes) is having an inhibitory effect upon the transgene. The use of insulator 
elements to flank the transgene supports this hypothesis (Roseman et al. , 1995). 
1.7 A NEW APPROACH TO IDENTIFYING DCRES 
Fitzsimons et al. , (1999) developed a reporter gene assay that can be used to screen X 
chromosomal DNA for DCREs. The components of this assay are the E. coli lacZ gene 
under the control of the constitutive promoter from the armadillo gene (this fusion is 
referred to as arm-lacZ). The arm promoter was chosen because it is constitutive and 
active in all tissues and all stages of development (Vincent et al. , 1994) in both males 
and females. arm-lacZ was flanked by SCS and SCS' insulator elements (specialised 
chromatin structures). SCS and SCS' sequences act as domain boundaries (Udvardy 
and Schedl, 1993 ). Domain boundaries establish a domain of independent gene activity 
by protecting against regulatory effects of surrounding chromosomal DNA. It has been 
found that arm-lacZ can respond to DCREs when on the X chromosome - one copy in 
males is expressed at twice the level of one copy in females. 
A limitation in studying X-linked genes is that the coding region must remain intact 
enough so its product can be assayed for. Using this newly developed assay system 
allows X-linked sequences to be subdivided as a reporter gene is detected in the assay 
rather than the gene product. Fitzsimons et al. , (1999) placed portions of DNA from the 
D. melanogaster X chromosome immediately upstream of the arm promoter. The 
hypothesis for these experiments was that any X-linked sequence containing DCREs 
would confer dosage compensation onto arm-lacZ in males and thereby produce twice 
the lacZ activity in males over females. As yet the DCREs remain unidentified. 
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1.8 RESEARCH OBJECTIVES 
This study has three main objectives. The first objective is to investigate the effect of 
roX genes on dosage compensation regulated by isolated DCREs. The second is to 
continue with the study begun by Fitzsimons et al., (1999) and isolate the DCREs 
involved in dosage compensation. However our study will focus particularly on regions 
of the X chromosome ( eg. 1 C) known to contain 'high affinity' binding sites for the 
MSL-1/MSL-2 core complex (Lyman et al., 1997). The final objective is to investigate 
further the possibility of Sxl regulating a second dosage compensation pathway 
throughout development. 
1.8.1 Specific Objectives 
Previous studies have been carried out to develop a new reporter gene assay system that 
can be used to screen X chromosomal DNA for DCREs. Fitzsimons et al. , (1999) 
developed and used this assay system on many constructs containing X-linked 
fragments of DNA in the attempt to isolate the elusive DCREs. This study will utilise 
the arm-lacZ assay system developed by Fitzsimons et al. , (1999) to investigate the role 
of various X-linked DNA fragments in dosage compensation. 
The initial aim was to test if the roX genes are needed to be present in cis in order for a 
fragment containing a DCRE to cause a male specific increase in lacZ expression. It 
was found that the roX genes alone caused elevated lacZ expression ie. the roX genes 
contained DCREs. Consequently the initial objective was modified to test if roX 
cDNAs and fragments of roX genes contained DCREs. 
The second aim of this study was to determine if DNA fragments from the tip of the X 
chromosome, in particular the region that shows "high affinity" binding with the MSL-
1 /MSL-2 core complex. The assay system will also be used to look for DCREs in these 
X-linked DNA fragments. The presence of DCREs would be confirmed by an increase 
in lacZ expression in males 
The third aim was to investigate the role of Sxl in dosage compensation in females 
throughout development. The study aimed to determine if insertion of 3' UTR 
fragments from other X-linked genes (Sx/, Small Forked, and Cut) would cause a 
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decrease in female specific expression of lacZ. These 3' UTR fragments contained 3 or 
more Sxl binding sites and were inserted into the 3' UTR of arm-lacZ. 
The fourth and final aim also looked at Sxl involvement in dosage compensation. 
Experiments with msl-2 showed the Sxl binding sites were required in both the 3' and 5' 
UTR to get complete repression of translation. Previously Fitzsimons et al., (1999) 
showed insertion of a Runt 3' UTR fragment into the arm-lacZ 3' UTR caused a modest 
decrease in female lacZ expression. This study aimed to determine if an additional Sxl 
site in the 5' UTR of the arm-lacZ construct, carrying the Runt 3' UTR fragment, would 
result in a more dramatic decrease in female lacZ expression. 
